Résumé
L’examen endoscopique est une référence dans la prise en charge des maladies inflammatoires chroniques intestinales (MICI). Il sert à poser le diagnostic mais également à évaluer l’évolutivité de la maladie. Il est donc important de connaître et d’utiliser les scores simples et reproductibles. Si le CDEIS nécessite un certain apprentissage, le score de Rutgeerts, évaluant la récidive iléale après résection iléocolique et guidant l’attitude thérapeutique, est simple et doit être largement diffusé.
Abstract
Endoscopy is the gold standard for IBD diagnosis and care, but also for assessing the evolution of the disease. It is therefore essential to know and to use simple, reproducible scores. Although the CDEIS requires a certain amount of training to use, the postoperative recurrence Rutgeerts score easy to perform and providing validated and reproducible information for choice of treatment, should be widely used.
Article PDF
Avoid common mistakes on your manuscript.
Références
Baron JH, Connell AM, Lennard-Jones JE (1964) Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1:89–92
Rutgeerts P, Sandborn WJ, Feagan BG, et al (2005) Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 353:2462–2476
Schroeder KW, Tremaine WJ, Ilstrup DM (1987) Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerativecolitis. A randomized study. N Engl J Med 317:1625–1629
Powell-Tuck J, Day DW, Buckell NA, et al (1982) Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 27:533–537
Rachmilewitz D (1989) Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 298:82–86
Truelove SC, Witts LJ (1955) Cortisone in ulcerative colitis. Final report on a therapeutic trial. Br Med J 2:1041–1048
Alemayehu G, Jarneröt G (1991) Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol 86:187–190
Carbonnel F, Lavergne A, Lemann M, et al (1994) Colonoscopy for acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci 39:1550–1557
Carbonnel F, Gargouri D, Lémann M, et al (2000) Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 14:273–279
Nahon S, Bouhnik Y, Lavergne-Slove A (2002) Colonoscopy accurately predicts the anatomical severity of colonic Crohn’s disease attacks: correlation with findings from colectomy specimens. Am J Gastroenterol 97:3102–3107
Mary JY, Modigliani R (1989) Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Gut 30:983–989
Modigliani R, Mary JY, GETAID (1987) Reproducibility of colonoscopic findings in Crohn’s disease: a prospective multicenter study of interobserver variation. Dig Dis Sci 32:1370–1379
Sandborn WJ, Feagan BG, Hanauer SB, et al (2002) A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology 122:512–530
Landi B, Anh TN, Cortot A, et al (1992) Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Gastroenterology 102:1647–1653
D’Haens G, Van Deventer S, Van Hogezand R, et al (1999) Endoscopic and histological healing with infliximab antitumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology 116:1029–1034
Mary JY, Lemann M, Colombel JF, et al (2009) Endoscopic remission and response in Crohn’s disease: an objective definition using the CDEIS. Eur J Gastroenterol Hepatol (in press)
Rutgeerts P, Diamond RH, Bala M, et al (2006) Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 63:433–442
D’Haens G, Van Deventer S, Van Hogezand R, et al (1999) Endoscopic and histological healing with infliximab antitumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 116:1029–1034
Daperno M, D’Haens G, Van Assche G, et al (2004) Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 60(4):505–512
Sachar DB (1990) The problem of postoperative recurrence of Crohn’s disease. Med Clin North Am 71:183–188
Schivananda S, Hordjik ML, Pena AS, Mayberry JF (1989) Crohn’s disease: risk of recurrence and reoperation in a defined population. Gut 30:990–995
Whelan G, Farmer RG, Fazio VW, Goormastic M (1985) Recurrence after surgery in Crohn’s disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology 88:1826–1833
Rutgeerts P, Geboes K, Vantrappen G, et al (1990) Predictability of the postoperative course of Crohn’s disease. Gastroenterology 99:956–963
Rutgeerts P, Van Assche G, Vermeire S, et al (2005) Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double blind, placebo-controlled trial. Gastroenterology 128:856–861
Author information
Authors and Affiliations
About this article
Cite this article
Bouhnik, Y., Attar, A. & Treton, X. Les scores endoscopiques des MICI. Colon Rectum 3, 101–106 (2009). https://doi.org/10.1007/s11725-009-0151-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11725-009-0151-y